From: EQ-5D-5L and SF-6Dv2 health utilities scores of diffuse large B-cell lymphoma patients in China
 | N | % | EQ-5D-5L | F | P-value | SF-6Dv2 | F | P-value | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Utility value | SD | Lower range | Upper range | SE | Utility value | SD | Lower range | Upper range | SE | |||||||
Untreated newly diagnosed patients | ||||||||||||||||
 Unknown (untreated) | 2 | 0.34 | 0.857 | 0.203 | -0.967 | 2.680 | 0.144 | - |  | 0.636 | 0.290 | -1.969 | 3.241 | 0.205 | - |  |
Newly diagnosed patients on treatment | ||||||||||||||||
 CR (on treatment) | 36 | 6.19 | 0.785 | 0.142 | 0.737 | 0.833 | 0.024 | 4.36 | 0.006 | 0.549 | 0.155 | 0.497 | 0.602 | 0.026 | 4.22 | 0.007 |
 PR (on treatment) | 15 | 2.58 | 0.688 | 0.364 | 0.487 | 0.890 | 0.094 |  |  | 0.497 | 0.195 | 0.390 | 0.605 | 0.050 |  |  |
 PD (on treatment) | 11 | 1.89 | 0.472 | 0.357 | 0.233 | 0.712 | 0.108 |  |  | 0.304 | 0.223 | 0.155 | 0.454 | 0.304 |  |  |
 Unknown (on treatment) | 54 | 9.28 | 0.759 | 0.273 | 0.684 | 0.833 | 0.037 |  |  | 0.501 | 0.223 | 0.440 | 0.561 | 0.030 |  |  |
Patients completed the first-line treatment and were monitored for health | ||||||||||||||||
 CR (off treatment) | 305 | 52.41 | 0.883 | 0.176 | 0.863 | 0.903 | 0.010 | 0.89 | 0.445 | 0.714 | 0.191 | 0.692 | 0.735 | 0.011 | 2.15 | 0.093 |
 PR (off treatment) | 34 | 5.84 | 0.845 | 0.126 | 0.801 | 0.889 | 0.022 |  |  | 0.637 | 0.187 | 0.702 | 0.572 | 0.032 |  |  |
 PD (off treatment) | 6 | 1.03 | 0.852 | 0.189 | 0.654 | 1.050 | 0.077 |  |  | 0.657 | 0.202 | 0.446 | 0.869 | 0.082 |  |  |
 Unknown (off treatment) | 14 | 2.41 | 0.831 | 0.186 | 0.723 | 0.938 | 0.050 |  |  | 0.651 | 0.175 | 0.550 | 0.752 | 0.047 |  |  |
RR patients on treatment | ||||||||||||||||
 CR (on treatment) | 11 | 1.89 | 0.861 | 0.152 | 0.759 | 0.964 | 0.046 | 3.07 | 0.038 | 0.628 | 0.160 | 0.520 | 0.735 | 0.048 | 1.52 | 0.222 |
 PR (on treatment) | 12 | 2.06 | 0.658 | 0.246 | 0.502 | 0.814 | 0.071 |  |  | 0.477 | 0.295 | 0.290 | 0.665 | 0.085 |  |  |
 PD (on treatment) | 7 | 1.20 | 0.796 | 0.201 | 0.610 | 0.983 | 0.076 |  |  | 0.499 | 0.348 | 0.177 | 0.820 | 0.131 |  |  |
 Unknown (on treatment) | 16 | 2.75 | 0.535 | 0.409 | 0.317 | 0.753 | 0.102 |  |  | 0.410 | 0.251 | 0.276 | 0.544 | 0.063 |  |  |
RR patients completed at least one line of treatment after relapse and were monitored for health | ||||||||||||||||
 CR (off treatment) | 37 | 6.36 | 0.832 | 0.191 | 0.768 | 0.896 | 0.031 | 0.46 | 0.708 | 0.652 | 0.169 | 0.596 | 0.709 | 0.028 | 0.44 | 0.727 |
 PR (off treatment) | 14 | 2.41 | 0.876 | 0.148 | 0.789 | 0.960 | 0.040 |  |  | 0.692 | 0.162 | 0.598 | 0.785 | 0.043 |  |  |
 PD (off treatment) | 5 | 0.86 | 0.805 | 0.289 | 0.446 | 1.163 | 0.129 |  |  | 0.593 | 0.291 | 0.233 | 0.954 | 0.130 |  |  |
 Unknown (off treatment) | 3 | 0.52 | 0.746 | 0.145 | 0.387 | 1.105 | 0.083 |  |  | 0.704 | 0.257 | 0.067 | 1.341 | 0.148 |  |  |